Friday , September 21 2018
Home / Resources / Videos / Christophe Arbet-Engels, MD, Q7: How Does Empagliflozin Differ from Other SGLT-2 Inhibitors?

Christophe Arbet-Engels, MD, Q7: How Does Empagliflozin Differ from Other SGLT-2 Inhibitors?

Sep 28, 2015
 

Dr. Christophe Arbet-Engels talks about how empagliflozin differs from other SGLT-2 inhibitors already on the market such as canagliflozin and dapagliflozin, stating that empagliflozin is “very specific” to its target, but hasn’t yet been compared to the others so it is too early to tell what other differences there might be.

Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

See more SGLT-2 Resources